{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:33:36Z","timestamp":1778002416798,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The 32-item Motor Function Measure (MFM32) is a clinician-reported outcome measure used to assess the functional abilities of individuals with neuromuscular diseases, including those with spinal muscular atrophy (SMA). This two-part study explored the relationship between the functional abilities assessed in the MFM32 and activities of daily living (ADLs) from the perspective of individuals with Type 2 and Type 3 (non-ambulant and ambulant) SMA and their caregivers through qualitative interviews and a quantitative online survey.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In-depth, semi-structured, qualitative interviews were conducted with individuals with SMA and caregivers from the US. Subsequently, a quantitative online survey was completed by individuals with SMA or their caregivers from France, Germany, Italy, Poland, Spain, Canada, the United\u00a0States (US) and the UK. In both parts of the study, participants were asked to describe the ADLs considered to be related to the functional abilities assessed in the MFM32. Results from the qualitative interviews informed the content of the quantitative online survey.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Qualitative interviews were conducted with 15 adult participants, and 217 participants completed the quantitative online survey. From the qualitative interviews, all of the functional abilities assessed in the patient-friendly\u00a0MFM32 were deemed as related to one or more ADL. The specific ADLs that participants considered related to the patient-friendly MFM32 items could be grouped into 10 key ADL domains: dressing, mobility\/transferring, self-care, self-feeding, reaching, picking up and holding objects, physical activity, writing and technology use, social contact\/engagement, toileting and performing work\/school activities. These results were confirmed by the quantitative online survey whereby the ADLs reported to be related to each patient-friendly MFM32 item were consistent and could be grouped into the same 10 ADL domains.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study provides in-depth evidence from the patient\/caregiver perspective supporting the relevance of the patient-friendly MFM32 items to the ADLs of individuals with Type 2 and Type 3 SMA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-021-02166-z","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T06:02:32Z","timestamp":1617170552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Understanding the relationship between the 32-item motor function measure and daily activities from an individual with spinal muscular atrophy and their caregivers\u2019 perspective: a two-part study"],"prefix":"10.1186","volume":"21","author":[{"given":"Tina","family":"Duong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9923-3300","authenticated-orcid":false,"given":"Jessica","family":"Braid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Staunton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelie","family":"Barriere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fani","family":"Petridis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Reithinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosangel","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Jarecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mencia","family":"De Lemus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Gusset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ria","family":"Broekgaarden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharan","family":"Randhawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Arbuckle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Reif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lida","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"De Martini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Vuillerot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"issue":"9630","key":"2166_CR1","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH. Spinal muscular atrophy. Lancet (London, England). 2008;371(9630):2120\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(08)60921-6.","journal-title":"Lancet (London, England)"},{"issue":"8","key":"2166_CR2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","volume":"22","author":"CH Wang","year":"2007","unstructured":"Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027\u201349. https:\/\/doi.org\/10.1177\/0883073807305788.","journal-title":"J Child Neurol"},{"issue":"9","key":"2166_CR3","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.3390\/ijms21093297","volume":"21","author":"TH Chen","year":"2020","unstructured":"Chen TH. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand? Int J Mol Sci. 2020;21(9):3297. https:\/\/doi.org\/10.3390\/ijms21093297.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2166_CR4","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/archneurol.2010.373","volume":"68","author":"P Kaufmann","year":"2011","unstructured":"Kaufmann P, McDermott MP, Darras BT, Finkel R, Kang P, Oskoui M, et al. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol. 2011;68(6):779\u201386. https:\/\/doi.org\/10.1001\/archneurol.2010.373.","journal-title":"Arch Neurol"},{"issue":"2","key":"2166_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103\u201315. https:\/\/doi.org\/10.1016\/j.nmd.2017.11.005.","journal-title":"Neuromuscul Disord"},{"key":"2166_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jns.2019.10.1276","volume":"405","author":"MM Ryan","year":"2019","unstructured":"Ryan MM, De Vivo DC, Bertini E, Hwu WL, Crawford TO, Swoboda KJ, et al. Nusinersen in infants who initiate treatment in a presymptomatic stage of spinal muscular atrophy (SMA): interim results from the phase 2 nurture study. J Neurol Sci. 2019;405:250. https:\/\/doi.org\/10.1016\/j.jns.2019.10.1276.","journal-title":"J Neurol Sci"},{"issue":"5","key":"2166_CR7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.nmd.2017.01.018","volume":"27","author":"F Rouault","year":"2017","unstructured":"Rouault F, Christie-Brown V, Broekgaarden R, Gusset N, Henderson D, Marczuk P, et al. Disease impact on general well-being and therapeutic expectations of European type II and type III spinal muscular atrophy patients. Neuromuscul Disord. 2017;27(5):428\u201338. https:\/\/doi.org\/10.1016\/j.nmd.2017.01.018.","journal-title":"Neuromuscul Disord"},{"key":"2166_CR8","volume-title":"CureSMA: Voice of the patient report","author":"R Cruz","year":"2018","unstructured":"Cruz R, Lenz M, Belter L, Hobby K, Jarecki J, Smart T. CureSMA: Voice of the patient report. (2018). https:\/\/www.curesma.org\/wp-content\/uploads\/2018\/01\/SMA-VoP-for-publication-1-22-2018.pdf. Accessed October 2020."},{"issue":"1","key":"2166_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12883-015-0473-3","volume":"15","author":"Y Qian","year":"2015","unstructured":"Qian Y, McGraw S, Henne J, Jarecki J, Hobby K, Yeh WS. Understanding the experiences and needs of individuals with spinal muscular atrophy and their parents: a qualitative study. BMC Neurol. 2015;15(1):217. https:\/\/doi.org\/10.1186\/s12883-015-0473-3.","journal-title":"BMC Neurol"},{"issue":"7","key":"2166_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.nmd.2005.03.004","volume":"15","author":"C Berard","year":"2005","unstructured":"Berard C, Payan C, Hodgkinson I, Fermanian J, Group MFMCS. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord. 2005;15(7):463\u201370. https:\/\/doi.org\/10.1016\/j.nmd.2005.03.004.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"2166_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","volume":"17","author":"MC Pera","year":"2017","unstructured":"Pera MC, Coratti G, Forcina N, Mazzone ES, Scoto M, Montes J, et al. Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurol. 2017;17(1):39.","journal-title":"BMC Neurol"},{"issue":"6","key":"2166_CR12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.nmd.2011.02.014","volume":"21","author":"E Mazzone","year":"2011","unstructured":"Mazzone E, Bianco F, Martinelli D, Glanzman AM, Messina S, De Sanctis R, et al. Assessing upper limb function in nonambulant SMA patients: development of a new module. Neuromuscul Disord. 2011;21(6):406\u201312. https:\/\/doi.org\/10.1016\/j.nmd.2011.02.014.","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"2166_CR13","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.apmr.2013.01.014","volume":"94","author":"C Vuillerot","year":"2013","unstructured":"Vuillerot C, Payan C, Iwaz J, Ecochard R, Berard C, Group MFMS. Responsiveness of the motor function measure in patients with spinal muscular atrophy. Arch Phys Med Rehabil. 2013;94(8):1555\u201361. https:\/\/doi.org\/10.1016\/j.apmr.2013.01.014.","journal-title":"Arch Phys Med Rehabil"},{"issue":"2","key":"2166_CR14","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40120-020-00206-3","volume":"9","author":"D Trundell","year":"2020","unstructured":"Trundell D, Le Scouiller S, Gorni K, Seabrook T, Vuillerot C, the SMSG. Validity and Reliability of the 32-Item Motor Function Measure in 2- to 5-Year-Olds with Neuromuscular Disorders and 2- to 25-Year-Olds with Spinal Muscular Atrophy. Neurol Ther. 2020;9(2):575. https:\/\/doi.org\/10.1007\/s40120-020-00206-3.","journal-title":"Neurol Ther"},{"key":"2166_CR15","volume-title":"Patient-Focused Drug Development Guidance: Methods to Identify What is Important to Patients and Select, Develop or Modify Fit-for-Purpose Clinical Outcome Assessments. Discussion document","author":"Food and Drug Administration","year":"2018","unstructured":"Food and Drug Administration: Patient-Focused Drug Development Guidance: Methods to Identify What is Important to Patients and Select, Develop or Modify Fit-for-Purpose Clinical Outcome Assessments. Discussion document. 2018."},{"key":"2166_CR16","volume-title":"Patient-Focused Drug Development: Methods to Identify What Is Important to Patients, Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. Draft guidance","author":"Food and Drug Administration","year":"2019","unstructured":"Food and Drug Administration. Patient-Focused Drug Development: Methods to Identify What Is Important to Patients, Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. Draft guidance. 2019."},{"key":"2166_CR17","volume-title":"Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products","author":"Committee for Medicinal Products for Human Use","year":"2005","unstructured":"Committee for Medicinal Products for Human Use. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. London: European Medicines Agency; 2005."},{"key":"2166_CR18","unstructured":"B\u00e9rard C, Girardot F, Payan C. User\u2019s Manual: MFM-32 & MFM-20. https:\/\/mfm-nmd.org\/get-a-user-manual\/?lang=en Accessed January 2021."},{"key":"2166_CR19","volume-title":"Scientific Software Development GmbH B, Germany. Atlas.ti.software version 7","author":"ATLAS.ti","year":"2013","unstructured":"ATLAS.ti. Scientific Software Development GmbH B, Germany. Atlas.ti.software version 7. 2013."},{"issue":"2","key":"2166_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qual Res Psychol"},{"issue":"3","key":"2166_CR21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1586\/erp.10.30","volume":"10","author":"C Kerr","year":"2010","unstructured":"Kerr C, Nixon A, Wild D. Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):269\u201381. https:\/\/doi.org\/10.1586\/erp.10.30.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2166_CR22","first-page":"17","volume":"6","author":"U Kelle","year":"2005","unstructured":"Kelle U. \u201cEmergence\u201d vs. \u201cforcing\u201d of empirical data? A crucial problem of \u201cGrounded Theory\u201d reconsidered. Forum Qual Soc Res. 2005;6:17.","journal-title":"Forum Qual Soc Res"},{"key":"2166_CR23","unstructured":"Data Visualization | Microsoft Power BI. https:\/\/powerbi.microsoft.com\/en-us\/ (2020). Accessed."},{"issue":"6","key":"2166_CR24","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J, Ramsey D, Fanelli L, Young SD, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve. 2017;55(6):869\u201374. https:\/\/doi.org\/10.1002\/mus.25430.","journal-title":"Muscle Nerve"},{"key":"2166_CR25","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.nmd.2008.07.003","volume":"18","author":"E Mercuri","year":"2008","unstructured":"Mercuri E, Mayhew A, Muntoni F, Messina S, Straub V, Van Ommen GJ, et al. Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD\/ENMC workshop on outcome measures, 12th--13th May 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30th June--1st July 2007, Naarden, The Netherlands; conjoint Institute of Myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France. Neuromuscul Disord. 2008;18:894\u2013903.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"2166_CR26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/1471-2288-11-126","volume":"11","author":"A Scott","year":"2011","unstructured":"Scott A, Jeon S-H, Joyce CM, Humphreys JS, Kalb G, Witt J, et al. A randomised trial and economic evaluation of the effect of response mode on response rate, response bias, and item non-response in a survey of doctors. BMC Med Res Methodol. 2011;11(1):126. https:\/\/doi.org\/10.1186\/1471-2288-11-126.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"2166_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1471-2288-11-62","volume":"11","author":"S Sahlqvist","year":"2011","unstructured":"Sahlqvist S, Song Y, Bull F, Adams E, Preston J, Ogilvie D, et al. Effect of questionnaire length, personalisation and reminder type on response rate to a complex postal survey: randomised controlled trial. BMC Med Res Methodol. 2011;11(1):62. https:\/\/doi.org\/10.1186\/1471-2288-11-62.","journal-title":"BMC Med Res Methodol"}],"updated-by":[{"DOI":"10.1186\/s12883-021-02307-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000}}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02166-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-021-02166-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02166-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T09:03:11Z","timestamp":1631523791000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-021-02166-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2166"],"URL":"https:\/\/doi.org\/10.1186\/s12883-021-02166-z","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12883-021-02307-4","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]},"assertion":[{"value":"25 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12883-021-02307-4","URL":"https:\/\/doi.org\/10.1186\/s12883-021-02307-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval and oversight of the qualitative interview study was provided by Copernicus Group Independent Review Board, a centralized IRB in the US (approval reference number IRB 20192527). The online survey was conducted following market research principles consistent with British Healthcare Business Intelligence Association\u00a0guidelines for Adverse Event Reporting and General Data Protection Regulation guidelines, which are applicable to all countries. A link to the survey was sent to eligible participants and included an electronic informed consent form\u00a0where participants completed a tick box indicating consent to participate prior to survey completion.Ethics approval for the quantitative online survey\u00a0was not obtained in the UK since according to NHS Health Research Authority (HRA) guidelines and on completion of the HRA decision tool, it was determined that NHS Research Ethics Committee (REC) review was not required. In addition, the content of the survey included a reduced set of questions included in the qualitative interviews, which was approved by Copernicus Group Independent Review Board (approval reference number IRB 20192527).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent to publish anonymized individual quotes was obtained from participants who took part in the qualitative interviews. Consent to publish aggregate results was obtained from participants completing the survey.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HS and JB are employees and shareholders of Roche Products Ltd. JR and FP are employees of F. Hoffmann-La Roche Ltd. TD serves on advisory boards and receives consultancy fees for Roche, Biogen, Novartis and Cure SMA. CV is a PI for Roche clinical trials and has received consultancy fees from Roche, Biogen, and Avexis. AB, TD and CV received consultancy fees from Roche for this project. SR, JF, RA are employees of Adelphi Values, a health outcomes research agency commissioned by Roche to conduct the qualitative interview portion of the study and wrote the first draft of the manuscript. MDL has taken part in Advisory boards representing the patients\u2019 views for Biogen, Novartis and Roche. JJ is an employee of CureSMA, which receives funding from Roche\/Genentech for other distinct projects and has no competing personal interests. RC was an employee with CureSMA at the time of the study and has no conflicts to disclose. NG is a volunteer of SMA Europe and SMA Schweiz, mother of a child living with SMA, advisor and lecturer for Novartis Gene Therapies (AveXis) Biogen, Novartis, and Roche. LY, SR and ADM are employees of Charles River Associates commissioned by Roche to conduct the online survey. RB has no conflicts to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}